ArticleEvidence-based medicine2017

SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.

André J ScheenPubMed ↗Publisher ↗

No numbers read from the abstract.